Novartis’ Sandoz division is to provide generic medicines and biosimilars in Vietnam at-cost for the treatment of severe COVID-19 symptoms, under a memorandum of understanding signed between Novartis and Vietnam’s Ministry of Health.
Sandoz Provides COVID Portfolio At Cost In Vietnam
Swiss Firm’s ‘COVID-19 Pandemic Response Portfolio’ Encompasses 15 SKUs
Novartis has expanded its efforts to help low- and lower-middle-income countries “mitigate the impact of the pandemic and support healthcare systems,” after signing a memorandum of understanding with Vietnam’s Ministry of Health providing various treatments for COVID-19 at-cost.
More from Deals
More from Business
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
• By
With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.